ReviewInvestigational new drugs2019

Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?

Giandomenico Roviello et al.PubMed ↗Publisher ↗

No numbers read from the abstract.